Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma

Technology appraisal guidance
Reference number: TA269
Published: 12 December 2012
Last updated: 01 January 2015

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: addendum by Liverpool Research Implementation Group (LRiG)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: addendum by Liverpool Research
Implementation Group (LRiG)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: addendum by Liverpool Research Implementation Group (LRiG)
02 November 2012
(473.31 Kb 17 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 29 October 2012